Immunoglobulin therapy and thrombosis: Coincidence or causation?

Transfusion

Volumn 52, Issue 10, 2012, Pages 2075-2077

  Drelich, Douglass A ^a   Bray, Paul F ^a   Herman, Jay H ^b  

^a Cardeza Foundation for Hematologic Research   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PROCOAGULANT; VON WILLEBRAND FACTOR;

ANTICOAGULANT THERAPY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG DELIVERY SYSTEM; HEALTH INSURANCE; HUMAN; IMMUNOTHERAPY; MEDICAL RECORD REVIEW; MORBIDITY; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS;

FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; THROMBOSIS;

EID: 84868271620     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03868.x     Document Type: Review

References (4)

1. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
2. Requirements for the collection, processing, and quality control of blood, blood components, and plasma derivatives. WHO Technical Report Series 1989, No. 786, Annex 4.
3. McCarthy K, Stewart P, Sigman J, Read M, Keith JC Jr, Brinkhous KM, Nichols TC, Schaub RG,. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 2002; 87: 824-30.
4. Tiede A, Friedrich U, Stenmo C, Allen G, Giangrande P, Goudemand J, Hay C, Holmström M, Klamroth R, Lethagen S, McKenzie S, Miesbach W, Negrier C, Yuste VJ, Berntorp E,. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa). J Thromb Haemost 2011; 9: 1191-9.